The 
Louis, MO, U.S.A.). One hour prior to sacrifice, animals were given an intraperitoneal injection of 5-bromo-2-deoxyuridine (BrdU, Sigma Chemical Co., St. Louis, MO, U.S.A.), at a dose of 100mg/ kg body weight. Each rat was killed by decapita tion, and the dorsolateral prostate was removed.
Organ weight
The weight of the dorsolateral prostates was recorded (absolute weight). Weight relative to body weight (relative weight) was calculated.
Histopathological examination
The dorsolateral prostates were fixed in 0.1 M phosphate-buffered 10% formalin, embedded in paraffin, mounted and stained with hematoxylin and eosin (HE). 
Results

Prostatic weights
The dorsolateral prostatic weight is shown in Table 1 . Those of the intact and castrated groups were comparable. Statistically significant increase was noted in the absolute (p<0.05) and relative (p<0.01) weight of the dorsolateral pros tate of the castrated rats treated with testosterone plus E2.
Histopathological and immunocytochemical findings Group 1 (Intact control)
Epithelial cells lining the dorsolateral prostate were columnar and the nuclei were located mainly in basal portion of the cells (Fig. 1A) .
A few BrdU-positive nuclei were observed in the glandu lar epithelial cells (Table 1 ). In the glandular epithelial cells, immunohistochemical localization of GSH-PO was weak or negative (Fig 2A) . AR was localized exclusively in the nuclei of the epith elial cells (Fig. 3A) . No immunostaining was observed in the nuclei when the section were in cubated with preimmune serum. Group 2 (Castration) Two days after castration, the height of glan dular epithelial cells was slightly reduced (Fig.  1B) . BrdU-positive nuclei in the glandular epith elial cells were rarely seen (Table 1) . Both GSH PO (Fig. 2B) and AR (Fig. 3B) were negative or very weak in the glandular epithelial cells.
Group 3 (Castration + Testosterone)
The glandular epithelial cells were of a high columnar shape (Fig. 1C) . The number of BrdU -positive nuclei was increased compared with intact control (Table 1) . GSH-PO was stained in those glandular epithelial cells (Fig. 2C ). In addition, nuclear immunostaining of AR in the glandular epithelial cells was also observed (Fig. 3C ). Group 4 (Castration + Testosterone + E2) The glandular epithelial cells were high, columnar, and showed an increased number of papillary projections extending into acini (Fig.  1D ). In addition, the epithelium showed a highly secretory appearance.
Interacinar stroma was also proliferated.
The number of BrdU-positive nuclei was greatly increased compared to the other experimental groups (Table 1) . Immunohisto chemical localization of GSH-PO staining was stronger than that of Group 3. In addition, the glandular epithelial cells showed uniformly intense nuclear immunostaining for AR (Fig. 3D) . Furthermore, AR was also detected in the nuclei of the stromal fibro-muscular cells. Previously, we demonstrated that the intensity of GSH-PO staining in the glandular epithelial cells of the ventral prostate decreased following castration, and could be reversed by testosterone administration to the castrated rats1. We there fore postulated that prostatic GSH-PO may be testosterone-dependent.
In the present study, we found that immunohistochemical staining of GSH PO in the glandular epithelium of the dorsolateral prostate was clearly responsive to testosterone alone or in combination with E2. Therefore, it seems likely that GSH-PO protein synthesis in the glandular epithelium of the dorsolateral prostate can be enhanced (induced ?) by sex hormones such as testosterone and E2. In fact, the significant increase of GSH-PO protein triggered by lipid peroxides has also been demonstrated in an experi mental system of inactivation and reactivation of the arachidonate cascade in rat peritoneal macrophages20.21 These findings indicated that increased levels of lipid peroxides (or peroxida tion) enhanced the expression of GSH-PO, oP, in other words, the decrease of lipid peroxides might reduce the expression. We suggest that lipid peroxidation was increased in the dorsolateral prostate by the testosterone alone, or testosterone plus E2-treatment.
Further work in this area is 
